Pfizer reported first-quarter 2026 revenue of $14.45 billion, up 5% year-over-year, with adjusted earnings of $0.75 per share beating the $0.72 consensus. Launched and acquired products generated $3.1 billion with 22% operational growth as Eliquis jumped 13% to $2.17 billion, while the COVID franchise collapsed — vaccine revenue fell 59% to $232 million and Paxlovid dropped 62% to $186 million.

The Metsera-derived obesity drug PF-3944 (formerly MET-097i) delivered 12.3% weight loss at week 28 in the Phase IIb VESPER-3 trial on monthly dosing, positioning Pfizer to challenge Novo Nordisk and Eli Lilly with ultra-long-acting peptides. Management said Pfizer plans to launch 10 Phase III studies this year and is targeting first Metsera approval in 2028, with broader market presence by 2029.

Pfizer reaffirmed full-year guidance of $59.5–62.5 billion in revenue and $2.80–3.00 adjusted EPS, returned $2.4 billion to shareholders via dividends, and noted roughly $7 billion in business-development capacity remains.